Inosamin

Eplerenone, the active ingredient in Inosamin, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It selectively blocks aldosterone binding, helping to control blood pressure and reduce fluid overload in adults with hypertension, heart failure, or after a myocardial infarction.

GNH USA supplies Inosamin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Eplerenone is used in conditions where aldosterone excess contributes to cardiovascular disease. - Hypertension: lowers blood pressure by promoting sodium excretion and potassium retention. - Heart failure: improves survival and reduces hospitalizations by decreasing fluid overload. - Post‑myocardial infarction: reduces risk of cardiovascular death and heart‑failure progression in patients with left‑ventricular dysfunction.

Eplerenone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hyperkalemia: can lead to cardiac arrhythmias. - Renal impairment: worsening kidney function. - Allergic reactions: including rash, angioedema, or anaphylaxis.

Before initiating therapy, several safety considerations should be observed. - Monitor potassium levels: regular blood tests are required to detect hyperkalemia. - Assess renal function: adjust use in patients with impaired kidney function. - Avoid use with potassium‑sparing diuretics: increased risk of high potassium. - Caution in elderly: higher susceptibility to hypotension. - Store at room temperature: keep in the original container, protect from moisture and light.

Eplerenone interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors or ARBs: additive effect on potassium and renal function. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase eplerenone plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and affect kidney function. - Digoxin: increased risk of toxicity due to electrolyte changes. - Thiazide diuretics: may counteract potassium‑retaining effect of eplerenone.